DNA methyltransferases Inhibitors
1 drugsAbout DNA methyltransferases
DNA methyltransferases (DNMTs) are a family of enzymes that catalyze DNA methylation, a process that alters gene expression without changing the DNA sequence. They play a crucial role in epigenetics by adding a methyl group to DNA.
DNMTs are compelling targets for drug development, particularly in oncology, due to their involvement in gene regulation. There is currently no genetic evidence directly linking DNMTs to specific diseases.
DNMTs are targeted by one FDA-approved drug, ONUREG, a small molecule from Bristol-Myers Squibb approved in 2020 for oncology indications.
Strategic Insights
ℹ️ How we calculate- phase1 represents biological uncertainty with 42% completion.
Top DNA methyltransferases Drugs
Bristol-Myers Squibb is the only company with an approved drug targeting DNMTs.
Low competition suggests opportunity, but also consider potential market entry barriers or target validation concerns.
DNA methyltransferases Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets DNA methyltransferases, using small molecule modality.
Explore alternative modalities like antibodies or PROTACs to differentiate from existing therapies.
DNA methyltransferases Clinical Trials 523 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 244 | 78 | 72 | 86 | 52% |
| Phase 2 | 217 | 68 | 36 | 108 | 65% |
| Phase 3 | 56 | 15 | 13 | 27 | 54% |
| Phase 4 | 6 | 1 | 1 | 4 | 50% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Phase 3 Readout Calendar Pro
2 Phase 3 trials testing approved DNA methyltransferases drugs across all sponsors.
Coverage: trials whose intervention is an approved drug targeting DNA methyltransferases. Pre-approval candidates with development codes (e.g. AZD0901, MK-7240) are not yet linked. Anchored on CT.gov primary completion date.
DNA methyltransferases Drug Approval Timeline (2020 - 2020)
The first and only drug, ONUREG, was approved in 2020.
Recent approval suggests renewed interest, but also indicates early stage of market saturation.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 405 clinical trials targeting DNA methyltransferases.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities